# Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone

> **NCT02344004** · PHASE3 · COMPLETED · sponsor: **Insmed Incorporated** · enrollment: 336 (actual)

## Conditions studied

- Mycobacterium Infections, Nontuberculous

## Interventions

- **DRUG:** LAI (Liposomal Amikacin for Inhalation) 590 mg

## Key facts

- **NCT ID:** NCT02344004
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-27
- **Primary completion:** 2018-07-03
- **Final completion:** 2019-04-03
- **Target enrollment:** 336 (ACTUAL)
- **Last updated:** 2020-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02344004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02344004, "Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02344004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*